Telo Genomics

Telo Genomics Current Assets

The Current Assets of Telo Genomics (TELO.V) as of Oct 17, 2026 is 26,500.00 CAD.

Current Assets

26,500.00CAD

Last updated:

Current Assets of Telo Genomics is 2025 26,500.00 CAD. Current Assets of Telo Genomics was 2024 0.00 CAD. It decreases by % higher compared to the previous year.

The Telo Genomics Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
107,831.00 CAD
Jan 1, 2019
82,956.00 CAD
Jan 1, 2020
1.04 M CAD
Jan 1, 2021
3.76 M CAD
Jan 1, 2022
2.79 M CAD
Jan 1, 2023
2.78 M CAD
Jan 1, 2024
0.00 CAD
Jan 1, 2025
26,500.00 CAD
The Telo Genomics Current Assets history
YEARCurrent AssetsYoY
26,500.00CAD—
0.00CAD-100.00%
2.78 MCAD-0.27%
2.79 MCAD-25.90%
3.76 MCAD+262.54%
1.04 MCAD+1,150.47%
82,956.00CAD-23.07%
107,831.00CAD-92.97%
1.53 MCAD+324.60%
361,042.00CAD-21.50%
459,929.00CAD-9.23%
506,698.00CAD-6.54%
542,170.00CAD+668.29%
70,568.00CAD+0.81%
70,000.00CAD-41.67%
120,000.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Telo Genomics Stock analysis

What does Telo Genomics do? Telo Genomics Corp, a biotechnology company based in Toronto, Ontario, focuses on developing and commercializing technological products aimed at personalizing treatment plans for patients with specific conditions. The company, which went public on February 15, 2012, is engaged in the development of predictive diagnostic tools. Its lead product, TeloView SMM, is a high-complexity molecular assay designed for clinical use. TeloView SMM provides physicians with information to guide treatment decisions for patients with Smoldering Multiple Myeloma. Through proprietary telomere-based analysis, the assay identifies high-risk patients who may benefit from earlier intervention and distinguishes them from low-risk patients with a more stable disease course who do not require immediate treatment. Telo Genomics Corp operates through its wholly owned subsidiary, Telo Genomics Holdings Corp., which is developing diagnostic and prognostic products for diseases exhibiting genomic instability. The company's website is www.telodx.com. Telo Genomics Corp is listed on the Canadian market under the ticker TELO.V with ISIN CA87975M2085. Telo Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telo Genomics stock

Current Assets of Telo Genomics is 26,500.00 CAD in 2025.

On Eulerpool you can find the complete historical development of Current Assets Telo Genomics since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Telo Genomics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Telo Genomics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Telo Genomics